Achilles Therapeutics

Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting neoantigens: protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Achilles Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Achilles Therapeutics balance sheet

Report period20192020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Achilles Therapeutics cash flows

Report period20192020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Achilles Therapeutics multipliers

Report period20192020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Achilles Therapeutics profitability

Report period20192020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Achilles Therapeutics assets
Achilles Therapeutics cash flows

Achilles Therapeutics dividend policy

The company doesn't provide dividends

Achilles Therapeutics shares

TickerNameTypeNominal valueISINPrice
ACHL:USAchilles TherapeuticsCommon share-US00449L1026$0.99
Achilles Therapeutics news
10.05.2022
Achilles Therapeutics' GAAP loss for 3 months of 2022 was $17.355 million, up 26.1% from $13.765 million in the previous year.
Source: {source} pictogram ir.achillestx.com
Pictogram next
01.03.2022
Achilles Therapeutics' GAAP loss for 2021 was $61.099 million, up 84% from $33.199 million the previous year.
Source: {source} pictogram ir.achillestx.com
Pictogram next
09.11.2021
Achilles Therapeutics' GAAP loss for 9M 2021 was $42.869 million, up 2.1 times from $20.279 million in the previous year.
Source: {source} pictogram ir.achillestx.com
Pictogram next
All Achilles Therapeutics news
General information
Company nameAchilles Therapeutics
Tags#biotechnology, #pharmacy, #cancer treatment
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address245 Hammersmith Road London W6 8PW United Kingdom
Mailing address245 Hammersmith Road London W6 8PW United Kingdom
Websiteir.achillestx.com